+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 6Years - 40Years
All Genders
ID04781972

Brain Imaging Study of Methylphenidate Effects on Neural Activity in ADHD Patients Using a Double-Blind Crossover Design

Led by Johns Hopkins University · Updated on 2026-10-27

30

Participants Needed

1

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying adults with ADHD to find brain imaging markers that can predict how well methylphenidate works in treating ADHD symptoms. The study focuses on changes in brain activity during tasks and the levels of glutamate in the brain after taking methylphenidate. This is a phase 4, double-blind, randomized crossover study involving a single dose of medication or placebo. Participants will receive one oral dose of methylphenidate 10 mg or 15 mg and, after a one-week washout period, a matching placebo in a crossover design, or vice versa. Each treatment session is followed by brain scans using functional MRI and magnetic resonance spectroscopy to measure task-related brain activity and glutamate levels. During the study, participants undergo neuropsychological testing along with MRI scans after each dose. Researchers measure brain responses about 90 minutes and 2 hours after dosing to evaluate brain activity and chemical changes. The study monitors participants over the treatment sessions to assess neural effects and treatment response, with participation lasting for the duration of the crossover protocol.

CONDITIONS

Brief Title

Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD

Research Team

K

Kristin L Bigos, PhD

R

Robyn Wiseman, BS

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here